İnflamatuar Barsak Hastalığında Adalimumab Tedavisinin Demir Parametreleri ve Anemi Üzerindeki Etkileri

Öz

Amaç: Bu çalışmada, Adalimumab tedavisinin inflamatuar barsak hastalığında (İBH) demir parametreleri ve aneminin seyri üzerindeki etkisini değerlendirmek amaçlanmıştır. Gereç ve yöntemler: 2016-2019 tarihleri arasında Sanko Üniversitesi Tıp Fakültesi Gastroenteroloji polikliniğinde takipli ve İBH nedeniyle Adalimumab tedavisi uygulanan 33 hasta (19 Crohn ve 14 ülseratif kolit) çalışmaya dahil edilmiştir. Hastaların; yaş, cinsiyet, laboratuvar verileri (kan hemoglobin (Hb), hematokrit (Htc), lökosit (WBC), trombosit (Plt), demir (Fe), demir bağlama kapasitesi (DBK), transferrin saturasyonu, ferritin, C‐reaktif protein (CRP) ve sedimantasyon düzeyleri) kaydedilmiştir. Tedavi öncesi ve 6. aydaki değerler karşılaştırılmıştır. Klinik aktivite ülseratif kolit için ortalama parsiyel Mayo skoru (pMayo) ve Crohn hastalarında ortalama Harvey-Bradshaw Index (HBI) puanları karşılaştırılarak tedavi etkinliği değerlendirilmiştir. Değişkenlerin analizinde SPSS 26.0 programı kullanılmıştır. Değişkenler %95 güven düzeyinde incelenmiş olup p değeri 0,05 ten küçük anlamlı kabul edildi. Bulgular: Sedimantasyon, CRP ve Plt değerlerinde tedavi sonrasında düşüş; Hb, Htc ve demir değerlerinde anlamlı yükselme saptanmıştır. Transferrin satürasyonunda ise yükselme gözlenmiştir. Ancak bu istatistiksel olarak anlamlı fark oluşturmamıştır. Hb ve Htc değerlerindeki artışın ülseratif kolit grubunda daha fazla olduğu saptanmıştır. Klinik pMayo ve HBI skorlarında ise anlamlı düşüş olduğu saptanmıştır. Sonuç: İBH nedeniyle Adalimumab tedavisi uygulanan hastalarda aneminin düzeliyor olması hastaların yaşam kalitesini de iyileştirecektir. Bu da uzun ve düzenli takip gerektiren bu hastalıkta hastaların tedaviye inancını ve uyumunu arttıracaktır.

Anahtar Kelimeler

• inflamatuar barsak hastalığı
• ülseratif kolit
• demir
• anemi

Effects of Adalimumab Treatment on Iron Parameters and Anemia in Inflammatory Bowel Disease

Öz

Background: In this study, we aimed to evaluate the effect of Adalimumab treatment on iron parameters and the course of anemia in inflammatory bowel disease (IBD).
Materials and Methods: Thirty-three patients (19 Crohn's and 14 ulcerative colitis) who received Adalimumab treatment for IBD who were followed up in the Gastroenterology outpatient clinic of Sanko University Faculty of Medicine between 2016-2019 were included in the study. Age, gender, laboratory data (blood hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), platelet (Plt), iron (Fe), iron binding capacity (DBK), transferrin saturation, ferritin, C - reaktif protein ( CRP) and sedimentation levels) of the patients were recorded. Pre-treatment and 6th month values were compared. Clinical activity the efficacy of treatment was evaluated by comparing the mean partial Mayo score (pMayo) for ulcerative colitis and the mean Harvey-Bradshaw Index (HBI) scores in Crohn’s patients. SPSS 26.0 program was used in the analysis of variables. Variables were analyzed at a 95% confidence level and a p value of less than 0.05 was considered to be significant.
Results: Decrease in sedimentation, CRP and Plt values after treatment; and significant increase was found in Hb, Htc and iron values, respectively. An increase in transferrin saturation was observed. However, this did not create a statistically significant difference. It was determined that the increase in Hb and Htc values was more in the ulcerative colitis group. A significant decrease was found in clinical pMayo and HBI scores.
Conclusions: Anemia improves in patients treated with Adalimumab for IBD, and this improvement is more pronounced in patients with ulcerative colitis.

Kaynakça

1. 1. Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113-20.
2. 2. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007 Oct 1;26(7):987-1003.
3. 3. Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. Biologics. 2008 Dec;2(4):763-77.
4. 4. Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn's disease. BioDrugs. 2007;21(2):125-32; discussion 33-4.
5. 5. Bergamaschi G, Di Sabatino A, Albertini R, Ardizzone S, Biancheri P, Bonetti E, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010 Feb;95(2):199-205.
6. 6. Peyrin-Biroulet L, Van Assche G, Gomez-Ulloa D, Garcia-Alvarez L, Lara N, Black CM, et al. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017 Jan;15(1):25-36 e27.
7. 7. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008 Dec;14(12):1660-6.
8. 8. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980 Mar 8;1(8167):514.

9. 9. Johnson D, Bayele H, Johnston K, Tennant J, Srai SK, Sharp P. Tumour necrosis factor alpha regulates iron transport and transporter expression in human intestinal epithelial cells. FEBS Lett. 2004 Aug 27;573(1-3):195-201.
10. 10. Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood. 2002 Jul 15;100(2):474-82.
11. 11. Dignass AU, Gasche C, Bettenworth D, Birgegard G, Danese S, Gisbert JP, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015 Mar;9(3):211-22.
12. 12. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011 Sep;141(3):846-53 e1-2.
13. 13. Gasche C, Dejaco C, Waldhoer T, Tillinger W, Reinisch W, Fueger GF, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med. 1997 May 15;126(10):782-7.
14. 14. Ott C, Liebold A, Takses A, Strauch UG, Obermeier F. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol Res Pract. 2012;2012:595970..
15. 15. Rubin DT, Mulani P, Chao J, Pollack PF, Bensimon AG, Yu AP, et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis. 2012 May;18(5):818-25.
16. 16. Koutroubakis IE, Ramos-Rivers C, Regueiro M, Koutroumpakis E, Click B, Schwartz M, et al. The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Jul;21(7):1587-93.
17. 17. Corrado A, Di Bello V, d'Onofrio F, Maruotti N, Cantatore FP. Anti-TNF-alpha effects on anemia in rheumatoid and psoriatic arthritis. Int J Immunopathol Pharmacol. 2017 Sep;30(3):302-7.
18. 18. Pereira ICP, Sousa NCF, Pereira DMS, Mendes SJF, Muniz TF, Colares VLP, et al. Treatment with either leflunomide or adalimumab reduces anaemia in patients with rheumatoid arthritis. An Acad Bras Cienc. 2018 Aug;90(2 suppl 1):2161-6.
19. 19. Sakthiswary R, Syahrul Sazliyana S, Mohd Shahrir MS, Shahril NS, Hussein H. Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices. EXCLI J. 2012;11:142-9.
20. 20. Chaubal A, Pandey V, Choksi D, Poddar P, Ingle M, Phadke A, et al. Anemia in patients with ulcerative colitis in remission: A study from western India. Indian J Gastroenterol. 2017 Sep;36(5):361-5.
21. 21. Bengi G, Keyvan H, Durmaz SB, Akpinar H. Frequency, types, and treatment of anemia in Turkish patients with inflammatory bowel disease. World J Gastroenterol. 2018 Sep 28;24(36):4186-96.
22. 22. Hoivik ML, Reinisch W, Cvancarova M, Moum B, group Is. Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. Aliment Pharmacol Ther. 2014 Jan;39(1):69-76.
23. 23. Cavallaro F, Duca L, Pisani LF, Rigolini R, Spina L, Tontini GE, et al. Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. Can J Gastroenterol Hepatol. 2017;2017:6843976.
24. 24. Falsetti L, Sampaolesi M, Riccomi F, Nitti C. Adalimumab as a potential cause of drug-induced thrombocytopaenic microangiopathy. BMJ Case Rep. 2020 Mar 4;13(3).
25. 25. Harada Y, Yamamoto H, Sato M, Kodaira M, Kono T. Autoimmune hemolytic anemia during adalimumab treatment for plaque psoriasis. Intern Med. 2015;54(9):1103-4.
26. 26. Sanchez-Pujol MJ, Docampo-Simon A, Moscardo C, Betlloch-Mas I. Adalimumab-induced hemolytic anemia in a girl with psoriasis. Dermatol Ther. 2020 Jul;33(4):e13711.
27. 27. B Zbaras, L N Sam, M C Grimm Thrombotic thrombocytopenic purpura associated with adalimumab (Humira) treatment in Crohn disease. Intern Med J. 2013 Feb;43(2):216-7.
28. 28. Loftus EV, Reinisch W, Panaccione R, Berg S, Alperovich G, Bereswill M, et al. Adalimumab Effectiveness Up to Six Years in Adalimumab-naive Patients with Crohn's Disease: Results of the PYRAMID Registry. Inflamm Bowel Dis. 2019 Aug 20;25(9):1522-31.